What is Leerink Partnrs’ Estimate for JNJ Q3 Earnings?

Johnson & Johnson (NYSE:JNJ) – Equities research analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Johnson & Johnson in a report released on Thursday, January 23rd. Leerink Partnrs analyst D. Risinger forecasts that the company will earn $3.13 per share for the quarter. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.56 per share. Leerink Partnrs also issued estimates for Johnson & Johnson’s FY2025 earnings at $10.61 EPS, FY2026 earnings at $10.88 EPS and FY2027 earnings at $11.30 EPS.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.29 EPS.

Other equities analysts have also recently issued research reports about the stock. Guggenheim lifted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Citigroup dropped their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Barclays lifted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, January 23rd. Finally, Wells Fargo & Company lowered their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $170.44.

Johnson & Johnson Trading Down 1.5 %

JNJ stock opened at $150.63 on Monday. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a market capitalization of $362.65 billion, a PE ratio of 22.65, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. The company’s 50 day moving average price is $147.81 and its two-hundred day moving average price is $156.12. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.29%. Johnson & Johnson’s payout ratio is 74.59%.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. IFS Advisors LLC grew its stake in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the last quarter. Highline Wealth Partners LLC purchased a new stake in shares of Johnson & Johnson in the third quarter worth $31,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at $32,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter worth about $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its stake in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.